0001801170-25-000204
SEC filingNotes show $1.1B cash and securities, no debt, and no buyback or dividend activity.
As of June 30, 2025, the company held $0.5B in cash and cash equivalents and $0.6B in marketable securities, for a total liquidity position of $1.1B. Total debt was zero, with no borrowings outstanding. Shareholders' equity stood at $0.7B. The balance sheet remains debt-free and highly liquid.
The Notes to Financial Statements did not disclose any material purchase commitments, long-term supply agreements, or other contractual obligations. No off-balance-sheet arrangements were noted.
No share repurchases were executed during the six months ended June 30, 2025, and no new buyback authorization was announced. No dividends were declared or paid. There was no debt issuance or repayment activity. Capital expenditures were not separately disclosed in the Notes.
The company operates as a single reportable segment. No segment-level revenue, operating income, or geographic breakdown was provided in the Notes to the Financial Statements.
No cash flow statement figures were provided in the input document. The excerpt only lists section headers and page numbers without any numerical data. Therefore, no analysis can be performed on operating cash flow, capital expenditures, or free cash flow. The filing date is August 8, 2025, for Clover Health Investments, but the actual cash flow numbers are missing. To proceed, the full cash flow statement for the six months ended June 30, 2025 and 2024 is required.